Reyon Pharmaceutical Co Ltd Asset Resilience Ratio
Reyon Pharmaceutical Co Ltd asset resilience ratio. Reyon Pharmaceutical Co Ltd (102460) has an Asset Resilience Ratio of 0.01% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 102460 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Reyon Pharmaceutical Co Ltd (2008–2024)
Asset resilience ratio of Reyon Pharmaceutical Co Ltd from 2008 to 2024. This chart shows how Reyon Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Read 102460 total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Reyon Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 102460 current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩36.69 Million | 0.01% |
| Total Liquid Assets | ₩36.69 Million | 0.01% |
Asset Resilience Insights
- Limited Liquidity: Reyon Pharmaceutical Co Ltd maintains only 0.01% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Reyon Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Reyon Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Reyon Pharmaceutical Co Ltd Asset Resilience Ratio by Year (2008–2024)
Reyon Pharmaceutical Co Ltd asset resilience ratio by year from 2008 to 2024. The table below shows the annual Asset Resilience Ratio data for Reyon Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | ₩6.04 Million ≈ $4.10K |
₩499.99 Billion ≈ $338.84 Million |
-0.03pp |
| 2023-12-31 | 0.03% | ₩134.02 Million ≈ $90.83K |
₩499.78 Billion ≈ $338.69 Million |
-4.10pp |
| 2022-12-31 | 4.13% | ₩20.02 Billion ≈ $13.57 Million |
₩484.69 Billion ≈ $328.47 Million |
-2.29pp |
| 2021-12-31 | 6.42% | ₩30.71 Billion ≈ $20.81 Million |
₩477.98 Billion ≈ $323.92 Million |
-4.05pp |
| 2020-12-31 | 10.48% | ₩33.27 Billion ≈ $22.55 Million |
₩317.61 Billion ≈ $215.24 Million |
-9.02pp |
| 2019-12-31 | 19.49% | ₩53.50 Billion ≈ $36.26 Million |
₩274.48 Billion ≈ $186.01 Million |
-27.48pp |
| 2018-12-31 | 46.97% | ₩142.40 Billion ≈ $96.50 Million |
₩303.17 Billion ≈ $205.45 Million |
+18.40pp |
| 2017-12-31 | 28.57% | ₩83.11 Billion ≈ $56.32 Million |
₩290.84 Billion ≈ $197.10 Million |
+11.74pp |
| 2016-12-31 | 16.83% | ₩35.27 Billion ≈ $23.91 Million |
₩209.54 Billion ≈ $142.00 Million |
+6.03pp |
| 2009-12-31 | 10.80% | ₩8.85 Billion ≈ $6.00 Million |
₩81.91 Billion ≈ $55.51 Million |
-2.11pp |
| 2008-12-31 | 12.91% | ₩8.43 Billion ≈ $5.71 Million |
₩65.27 Billion ≈ $44.23 Million |
-- |
About Reyon Pharmaceutical Co Ltd
REYON Pharmaceutical Co., Ltd. manufactures and sells medicines. The company offers its products under the areas of adrenal corticosteroides; angiotensin II receptor antagonists; antibiotics; anticholinergics; antiemetic; antihypertensives; anti-inflammatory enzymes; antilipidemic, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer; antispasmodics; benign prostatic hypertrophy; cough … Read more